Drugs / Actinomycin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07194044 | Feb 2026 → Oct 2030 expected | Ewing sarcoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03885388 | Mar 2019 → Dec 2021 | chemotherapy-induced toxicity, gestational trophoblastic neoplasm | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | actinomycin | “Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6” NCT03885388 ↗ |
| Known as | ACTD | “Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6” NCT03885388 ↗ |
| Route | Intravenous | “intravenous (IV)” NCT03885388 ↗ |